首页> 外文期刊>BMC Pulmonary Medicine >Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials
【24h】

Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials

机译:随机双盲,多中心IIb / III期试验对东亚哮喘患者糠酸氟替卡松/维兰特罗的种族敏感性评估

获取原文
       

摘要

Fluticasone furoate (FF)/vilanterol (VI) is a once daily (OD) inhaled corticosteroid/long-acting β2-agonist combination asthma therapy approved in Japan and the EU. FF/VI efficacy and safety data from asthma studies including patients in East Asia were evaluated to assess ethnic sensitivity. Randomized, double-blind, multicenter Phase IIb/III trials were assessed. Change from baseline relative to placebo or twice-daily fluticasone propionate 500?μg in trough FEV1 was compared between patients from Japan (N?=?148) and Not-Japan (N?=?3,066; three studies). Adverse events (AEs), laboratory results, and electrocardiograms were compared between patients from Japan?+?Korea (N?=?188) and Not-Japan?+?Korea (N?=?3,840; five studies). For trough FEV1, improvements from baseline (least-squares mean difference [95?% confidence interval]) were reported for FF/VI 100/25?μg OD versus placebo at Week 12 (Japan: 0.323?L [0.104–0.542]; Not-Japan: 0.168?L [0.095–0.241]). Improvements from baseline (least-squares mean change [standard error]) were reported with FF/VI 200/25?μg OD at Week 24 (Japan: 0.355?L [0.1152]; Not-Japan: 0.396?L [0.0313]). A greater proportion of patients from Japan?+?Korea versus Not-Japan?+?Korea reported AEs in all treatment arms including placebo (FF/VI 100/25?μg: 79?% versus 57?%; FF/VI 200/25?μg: 64?% versus 45?%; placebo: 41?% versus 23?%). There were no notable differences in treatment-related or class-related AEs. No clinically significant changes in electrocardiogram assessments or statistically significant differences in 24?h urinary cortisol excretion were observed between the Japan?+?Korea and Not-Japan?+?Korea cohorts. Good efficacy and an acceptable safety profile were observed for FF/VI 100/25?μg and 200/25?μg OD in East Asian asthma patients; these globally recommended doses are appropriate for asthma patients in Japan. Clinicaltrials.gov registration numbers: NCT01165138 , NCT01134042 , NCT01086384 , NCT00603278 , NCT00603382 .
机译:糠酸氟替卡松(FF)/维兰特罗(VI)是日本和欧盟批准的每日一次(OD)吸入皮质类固醇/长效β2-激动剂联合哮喘治疗药物。评估了包括东亚患者在内的哮喘研究的FF / VI疗效和安全性数据,以评估种族敏感性。评估了随机,双盲,多中心IIb / III期试验。比较了来自日本(N = 148)和非日本(N = 3 066,三项研究)患者的FEV1谷值相对于安慰剂或每日两次丙酸氟替卡松500μg的基线相对变化。比较了日本+韩国(N = 188)和非日本+韩国(N = 3840;五项研究)患者的不良事件(AEs),实验室结果和心电图。对于低谷型FEV1,FF / VI 100/25?μgOD相对于安慰剂的基线较基线改善(最小二乘均方差[95%置信区间])(日本:0.323?L [0.104-0.542];日本以外:0.168?L [0.095–0.241]。据报道,第24周FF / VI 200/25?g OD相对基线有改善(最小二乘均值变化[标准误差])(日本:0.355?L [0.1152];日本以外地区:0.396?L [0.0313]) 。来自日本+韩国的患者相对于非日本+韩国的患者报告了包括安慰剂在内的所有治疗组的AE(FF / VI 100 /25μg:79 %% vs 57%; FF / VI 200 / 25微克:64%对45%;安慰剂:41%对23%)。与治疗相关或与类相关的不良事件没有显着差异。在日本+韩国和非日本+韩国人群中,未观察到心电图评估的临床显着变化或24小时尿皮质醇排泄的统计学差异。在东亚哮喘患者中,FF / VI 100 /25μg和200 /25μgOD观察到良好的疗效和可接受的安全性。这些全球推荐的剂量适用于日本的哮喘患者。 Clinicaltrials.gov注册号:NCT01165138,NCT01134042,NCT01086384,NCT00603278,NCT00603382。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号